Waxman to Head Key House Committee
In a sharp break with Washington tradition, Rep. Henry Waxman (D-Calif) unseated long-time top Democrat on the House Energy & Commerce Committee, John Dingell (D-Mich), to become the panel's new chairman.
Waxman to Head Key House Committee
In a sharp break with Washington tradition, Rep. Henry Waxman (D-Calif) unseated long-time top Democrat on the House Energy & Commerce Committee, John Dingell (D-Mich), to become the panel’s new chairman. The House Democratic caucus backed Waxman for the job after a hotly contested campaign in which Waxman claimed to be better positioned to work with the new Obama administration to enact environmental and health care legislation.
The change puts a long-time critic of the pharmaceutical industry at the helm of this all-important panel. All health care legislation fall under its purview, along with measures affecting the Food and Drug Administration and other federal health agencies. However, Waxman differs with Dingell more notably on environmental and clean air policy and less on health issues, making the change less dramatic for pharma and health care entities. Both Dingell and Waxman have long championed universal health care, and a top priority for the new chairman will be to pursue health reform legislation vigorously.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
